$15.6m for TriReme's third funding round:
This article was originally published in Clinica
Pleasanton, California-based TriReme Medical has raised $15.6m in new capital to fund the development and ongoing clinical trials of its single-balloon bifurcation stent system. The series C financing came from lead investor Three Arch Partners and Adams Street Partners. TriReme said its device has a lower profile than standard bifurcation stent systems. In addition, the delivery system is the only one of its kind that allows the doctor to actively determine the orientation of the stent prior to deployment, thereby ensuring precise positioning.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.